Jiangsu Hansoh Pharmaceutical Co. Ltd

BioNTech’s close to $1bn acquisition of Biotheus announced earlier this month marked another big M&A deal between a Chinese biotech and a foreign firm following AstraZeneca’s roughly $1.2bn buyou

Zai Lab’s antibody-drug conjugate (ADC) ZL-1310 appears set to disrupt a competitive landscape as a new force in previously treated, extensive-stage small cell lung cancer (ES-SCLC) following promisin

Over the past roughly three years, AstraZeneca PLC’s key oncology drugs, including for lung cancer, have been facing gathering clouds in China. Not only are Chinese homegrown rivals nibbling at market